Arcus Biosciences, Inc. (NYSE:RCUS) Given Average Rating of “Moderate Buy” by Analysts

Arcus Biosciences, Inc. (NYSE:RCUS) has been assigned a consensus recommendation of “Moderate Buy” from the eight brokerages that are covering the firm, MarketBeat reports. Two research analysts have rated the stock with a hold rating and six have issued a buy rating on the company. The average 12-month price target among brokerages that have covered the stock in the last year is $21.1429.

A number of equities analysts recently weighed in on RCUS shares. Wells Fargo & Company decreased their price target on Arcus Biosciences from $26.00 to $25.00 and set an “overweight” rating for the company in a research report on Thursday, August 7th. Morgan Stanley decreased their price target on Arcus Biosciences from $24.00 to $22.00 and set an “overweight” rating for the company in a research report on Friday, May 9th. Wall Street Zen upgraded Arcus Biosciences from a “strong sell” rating to a “hold” rating in a research report on Saturday. Barclays decreased their price target on Arcus Biosciences from $29.00 to $14.00 and set an “overweight” rating for the company in a research report on Wednesday, April 23rd. Finally, The Goldman Sachs Group decreased their price target on Arcus Biosciences from $15.00 to $13.00 and set a “neutral” rating for the company in a research report on Thursday, May 8th.

Arcus Biosciences Stock Performance

RCUS opened at $9.19 on Tuesday. The company has a quick ratio of 4.50, a current ratio of 4.50 and a debt-to-equity ratio of 0.18. The firm has a market cap of $977.56 million, a PE ratio of -2.90 and a beta of 0.89. The business has a fifty day simple moving average of $9.15 and a 200-day simple moving average of $9.38. Arcus Biosciences has a fifty-two week low of $6.50 and a fifty-two week high of $18.98.

Arcus Biosciences (NYSE:RCUS) last released its quarterly earnings results on Wednesday, August 6th. The company reported ($1.11) earnings per share for the quarter, beating analysts’ consensus estimates of ($1.14) by $0.03. Arcus Biosciences had a negative return on equity of 55.96% and a negative net margin of 109.56%. The business had revenue of $160.00 million during the quarter, compared to analyst estimates of $32.86 million. During the same quarter last year, the company posted ($1.02) EPS. Arcus Biosciences’s revenue for the quarter was up 310.3% on a year-over-year basis. As a group, equities analysts predict that Arcus Biosciences will post -3.15 EPS for the current fiscal year.

Institutional Inflows and Outflows

Several large investors have recently bought and sold shares of RCUS. CWM LLC increased its position in Arcus Biosciences by 233.6% in the 2nd quarter. CWM LLC now owns 5,441 shares of the company’s stock worth $44,000 after purchasing an additional 3,810 shares during the last quarter. PNC Financial Services Group Inc. increased its holdings in shares of Arcus Biosciences by 440.3% during the 2nd quarter. PNC Financial Services Group Inc. now owns 7,597 shares of the company’s stock valued at $62,000 after acquiring an additional 6,191 shares during the last quarter. Strs Ohio acquired a new position in shares of Arcus Biosciences during the 1st quarter valued at about $67,000. E Fund Management Co. Ltd. acquired a new position in shares of Arcus Biosciences during the 1st quarter valued at about $82,000. Finally, Lazard Asset Management LLC increased its holdings in shares of Arcus Biosciences by 3,321.3% during the 4th quarter. Lazard Asset Management LLC now owns 6,261 shares of the company’s stock valued at $93,000 after acquiring an additional 6,078 shares during the last quarter. 92.89% of the stock is owned by institutional investors and hedge funds.

About Arcus Biosciences

Arcus Biosciences, Inc, a clinical-stage biopharmaceutical company, develops and commercializes cancer therapies in the United States. The company's pipeline products include Domvanalimab, an anti-TIGIT antibody, which is in Phase 2 and Phase 3 clinical trial; and AB308, an investigational anti-TIGIT monoclonal antibody, which is in Phase 1b clinical trial to study people with advanced solid and hematologic malignancies.